Cocrystal Pharma, Inc.
COCP
$1.24
$0.065.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -21.58% | -53.72% | -59.68% | -62.94% | -50.63% |
| Gross Profit | 25.83% | 55.78% | 59.68% | 62.94% | 50.63% |
| SG&A Expenses | -12.22% | -18.01% | -25.78% | -22.57% | -11.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.93% | -42.35% | -49.55% | -51.91% | -40.32% |
| Operating Income | 20.53% | 43.75% | 49.55% | 51.91% | 40.32% |
| Income Before Tax | 20.88% | 44.29% | 49.55% | 48.29% | 29.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.88% | 44.29% | 49.55% | 48.29% | 29.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.88% | 44.29% | 49.55% | 48.29% | 29.94% |
| EBIT | 20.53% | 43.75% | 49.55% | 51.91% | 40.32% |
| EBITDA | 20.27% | 43.71% | 49.60% | 52.02% | 40.36% |
| EPS Basic | 38.58% | 53.09% | 54.07% | 49.05% | 29.88% |
| Normalized Basic EPS | 38.58% | 53.09% | 54.06% | 51.63% | 38.77% |
| EPS Diluted | 38.58% | 53.09% | 54.07% | 49.05% | 29.88% |
| Normalized Diluted EPS | 38.58% | 53.09% | 54.06% | 51.63% | 38.77% |
| Average Basic Shares Outstanding | 28.71% | 19.83% | 10.95% | 1.89% | -0.06% |
| Average Diluted Shares Outstanding | 28.71% | 19.83% | 10.95% | 1.89% | -0.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |